Grifols announces €500m redemption of 7.5% 2030 bonds to further optimize its capital structure

Barcelona, Spain, April 13, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, plans to redeem €500 million of its 7.5% Senior Secured Notes due 2030, which would reduce the outstanding amount of its highest-cost indebtedness as part of an ongoing strategy to reduce cash interest expense and strengthen its capital structure.

The partial redemption of 7.5% Senior Secured 2030 Notes would follow Grifols’ previously announced successful loan syndication and planned refinancing of its 2027 debt maturities, which includes a Secured Term Loan B that was significantly upsized to approximately €3 billion (equivalent) and an approximately $2 billion Secured Revolving Credit Facility. The syndication was supported by strong global investor demand and institutional backing. Following the closing of the refinancing, scheduled for April 14, Grifols will have no material debt maturities until October 2028. Together these proactive actions will strengthen the company’s balance sheet by reducing funded gross debt levels, lowering cash interest expense, improving its debt maturity profile, while maintaining strong liquidity levels.

Rahul Srinivasan, CFO of Grifols, said: “This is a further step forward in the execution of our financial strategy. By proactively redeeming our highest-cost debt, we will reduce our cash interest expense and further strengthen our balance sheet, while continuing to maintain strong liquidity levels.”

The closing of the new loan financing, which is subject to customary closing conditions, is a condition for the partial redemption of the 7.5% Senior Secured Notes due 2030 as well as the refinancing of the Company’s debt instruments which mature in 2028.